Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma

Journal of Clinical Pathology

Volumn 60, Issue 3, 2007, Pages 307-310

  Stadlmann, Sylvia ^a   Gueth, Uwe ^b   Wight, Edward ^b   Kunz Schughart, Leoni A ^c   Hartmann, Arndt ^c   Singer, Gad ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATINUM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER;

ADULT; AGED; CYCLOOXYGENASE 2; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PPAR GAMMA; PROTEIN ARRAY ANALYSIS; RECURRENCE;

EID: 33947373945     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.035717     Document Type: Article

References (37)

1. Fraser M, Leung B, Jahani-Asl A, et al. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003;1:66.
2. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001;7:395-400.
3. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806-11.
4. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000;83:1394-400.
5. Rumi MA, Sato H, Ishihara S, et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma, Br J Cancer 2001;84:1640-7.
6. Martelli ML, Iuliano R, Le Pera I, et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002;87:4728-35.
7. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9:1-9.
8. Panigrahy D, Shen LQ, Kieran MW, et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Invest Drugs 2003;12:1925-37.
9. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602.
10. Theocharis S, Margeli A, Vielh P, et al. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004;30:545-54.
11. Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Invest Drugs 2005;14:557-68.
12. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclo-oxygenase-2 and peroxisome proliferator-activated receptor-gamma. Int J Oncol 2002;20:1109-22.
13. Andela VB, Altuwaijri S, Wood J, et al. Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett 2005;579:1765-9.
14. Lu J, Imamura K, Nomura S, et al. Chemopreventive effect of peroxisome proliferator-activoted receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005;65:4769-74.
15. Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-9.
16. Burstein HJ, Demetri GD, Mueller E, et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003;79:391-7.
17. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000;97:10990-5.
18. Inoue H, Tanabe T, Umesono K. Feedback control of cyclo-oxygenase-2 expression through PPARgamma. J Biol Chem 2000;275:28028-32.
19. Ikawa H, Kameda H, Kamitani H, et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 2001;267:73-80.
20. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22:1379-83.
21. Badawi AF, Eldeen MB, Liu Y, et al. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 2004;64:1181-9.
22. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840.
23. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-11.
24. Lou WZ, Shen K, Zhang Y, et al. Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 2004;39:529-32.
25. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 2004;92:927-35.
26. Raspollini MR, Amunni G, Villanucci A, et al. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 2005;15:255-60.
27. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160:893-903.
28. Zhang GY, Ahmed N, Riley C, et al. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma Br J Cancer 2005;92:113-19.
29. Sakamoto A, Yokoyama Y, Umemoto M, et al. Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer 2004;91:633-8.
30. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
31. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
32. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-10.
33. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med 2005;114:257-68.
34. Koto M, Kusumi T, Tsuchida S, et al. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. Cancer Res Clin Oncol 2004;130:73-9.
35. Nunez NP, Liu H, Meadows GG. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 2005;236:133-41.
36. Matsumoto Y, Ishiko O, Deguchi M, et al. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001;8:31-6.
37. Erkinheimo TL, Lassus H, Finne P, et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/ neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004;10:538-45.